# Health Protection Scorecard covering Northamptonshire Integrated Care System, to be presented at Health Protection Committee

Northamptonshire ICS;  North & West Northamptonshire

April 2023

Top 3 Achievements:

- Impressive uptake in diabetic eye screening

- Tuberculosis incidence rate per 100,000 has decreased

- Antenatal screening performance improving

Gaps:

- Decline in cancer screening performance, still below national targets

| Data sources | |
|---|---|
| | Cover of vaccination evaluated rapidly (COVER) programme 2021 to 2022: quarterly data - GOV.UK (www.gov.uk) |
| COVER | [ARCHIVED CONTENT] Cover of vaccination evaluated rapidly (COVER) programme 2021 to 2022: quarterly data - GOV.UK (nationalarchives.gov.uk) |
| | Cover of vaccination evaluated rapidly (COVER) programme 2022 to 2023: quarterly data - GOV.UK (www.gov.uk) |
| | NHFT quarterly return for local data |
| Population vaccination coverage - HPV vaccination coverage for two doses (females 13-14 years old) New data | https://www.gov.uk/government/publications/hpv-vaccination-coverage-in-adolescent-females-and-males-in-england-2019-to-2020 |
| | https://fingertips.phe.org.uk/search/HPV#page/4/gid/1/pat/6/ati/102/are/E10000021/iid/92896/age/296/sex/2/cat/-1/ctp/-1/cid/4/Tuberculosism/1/page-options/car-do-0 |
| MenACWY | https://fingertips.phe.org.uk/search/MenACWY#page/4/gid/1/pat/6/par/E12000004/ati/102/are/E10000021/iid/93648/age/311/sex/4/cat/-1/ctp/-1/cid/4/Tuberculosism/1/page-options/car-do-0 |
| | https://www.gov.uk/government/publications/meningococcal-acwy-immunisation-programme-vaccine-coverage-estimates |
| | ImmForm for the most recent data |
| Childhood - Flu | https://www.gov.uk/government/statistics/seasonal-flu-vaccine-uptake-in-gp-patients-winter-2018-to-2019 |
| | ImmForm for the most recent data |
| School age - Flu | Annual figure: https://www.gov.uk/government/collections/vaccine-uptake#menb-vaccine-uptake |
| | Monthly figure: ImmForm |
| Adult - Flu | https://www.gov.uk/government/statistics/seasonal-flu-vaccine-uptake-in-gp-patients-winter-2017-to-2018 |
| | ImmForm |
| Population vaccination coverage - PPV (%) | Health Protection, Fingertips tool |
| | Pneumococcal polysaccharide vaccine (PPV): vaccine coverage estimates - GOV.UK (www.gov.uk) |
| Population vaccination coverage - Shingles vaccination coverage (70 years old) | ImmForm, Shingles Immunisation Vaccine Uptake Monitoring Programme, GOV.UK |
| Tuberculosis Incidence (three year) | |
| Proportion of pulmonary Tuberculosis cases starting treatment within four months of symptom onset | Tuberculosis strategy monitoring indicators, Fingertips tool |
| Proportion of Tuberculosis cases offered an HIV test | |
| Acute hepatitis B incidence rate/100,000 | Liver disease Profiles, Fingertips tool |
| Under 75 mortality rate from hepatitis B related end-stage liver disease/hepatocellular carcinoma | Public Health Profiles - PHE |
| Persons entering drug misuse treatment - Percentage of eligible persons completing a course of hepatitis B vaccination | Quarterly data for substance misuse treatment client indicators from NDTMS (restricted statistics) |
| Hospital admission rate for hepatitis B related end-stage liver disease/hepatocellular carcinoma | |
| Hepatitis C detection rate/100,000 | Public health profiles - OHID (phe.org.uk) |
| Under 75 mortality rate from hepatitis C related end-stage liver disease/hepatocellular carcinoma | Public health profiles - OHID (phe.org.uk) |
| Hospital admission rate for hepatitis C related end-stage liver disease/hepatocellular carcinoma | |
| Persons in drug misuse treatment who inject drugs - Percentage of eligible persons who have received a hepatitis C test | Quarterly data for substance misuse treatment client indicators from NDTMS (restricted statistics) |
| New HIV diagnosis rate / 100,000 aged 15+ | Unitary update from april 2021 |
| HIV diagnosed prevalence rate per 1,000 aged 15-59 | Sexual Health and Reproductive Profiles, Fingertips tool |
| HIV late diagnosis (%) | |
| HIV testing coverage, total (%) | |
| All new STI diagnoses | |
| Syphilis diagnoses / 100,000 populationNew data | |
| Gonorrhoea diagnosis / 100,000 populationNew data | |
| Chlamydia detection rate / 100,000 aged 15-24 | |
| Cancer Screening | |
| Cervical cancer | https://digital.nhs.uk/data-and-information/publications/statistical/cervical-screening-programme/cervical-screening-programme-coverage-statistics-management-information |
| | https://app.powerbi.com/view?r=eyJrIjoiZDI1YWE4NTQtMjQ0Mi00OGRhLTg1NGMtNTQxYjMwMjVjOTMyIiwidCI6IjUwZjYwNzFmLWJiZmUtNDAxYS04ODAzLTY3Mzc0OGU2MjllMiIsImMiOjh9 |
| | https://www.gov.uk/government/publications/nhs-screening-programmes-kpi-reports-2017-to-2018 |
| Bowel | PHOF, Fingertips tool |
| Breast | |
| AAA | Fingertips tool, NHS Screening Programmes KPI Reports |
| DES | |
| C.Diff | AMR local indicators, Fingertips tool |
| MRSA | AMR local indicators, Fingertips tool |
| MSSA | AMR local indicators, Fingertips tool |
| E-Coli | AMR local indicators, Fingertips tool |
| Antenatal sreening - HIV | |
| Antenatal screening - Hepatitis B | |
| Antenatal screening - Sickle cell Thalassaemia | |
| Down syndromn screening | https://www.gov.uk/government/collections/nhs-population-screening-programmes-kpi-reports |
| Antenatal screening - Newborn blood spot | |
| Coverage % Newborn Hearing screening | |
| Antenatal screening - Newborn Hearing | |
| Coverage (Newborn) % Newborn and infant physical examination | |

# Health Protection Scorecard, County Indicators

| Data Quality Key | |
|---|---|
| >1 year | Very recent data, likely to be reliable and useful |
| 1 - 2 years | Recent data, likely to be reliable and useful |
| 2 - 3 years | Old data, possibly reliable but should not be used without a data caveat |
| 3+ years | Old data, unlikely to be reliable and should not be used |

Compare to target

Compare to last data collection period

| Meeting national target | | Below national target | | No national target |
|---|---|---|---|---|
| Increased | ◑ | Reduced | ◑ | No change |
| Good | ⬆ ⬇ | Bad | ⬆ ⬇ | ⮕ |

| Area | | Indicator | Time since last update | Good is | National Target | Comparator | | | Northamptonshire ICS | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | Previous Data | | | Current Data | | | |
| | | | | | | Date | East Midlands | England | Period | Outturn | Average (crude)/Outturn | Period | Outturn | Average (crude)/Outturn | RAG |
| **Immunisation** | | | | | | | | | | | | | | | |
| Childhood | 1 Year old | Population vaccination coverage - Dtap / IPV / Hib | >1 year | High | 95% | 2022/23, Q1 | 93.5% | 92.0% | 2021/22, Q1 | 93.7% | 94.1% | 2022/23, Q1 | 92.9% | 93.6% | ◑ |
| | | | | | | 2022/23, Q2 | 93.5% | 92.1% | 2021/22, Q2 | 93.0% | | 2022/23, Q2 | 92.5% | | |
| | | | | | | 2022/23, Q3 | 93.4% | 91.9% | 2021/22, Q3 | 94.4% | | 2022/23, Q3 | 94.5% | | |
| | | | | | | 2021/22, Q4 | 94.0% | 91.9% | 2020/21, Q4 | 95.2% | | 2021/22, Q4 | 94.6% | | |
| | 2 Years old | Population vaccination coverage - Dtap / IPV / Hib | >1 year | High | 95% | 2022/23, Q1 | 94.7% | 92.9% | 2021/22, Q1 | 95.6% | 95.0% | 2022/23, Q1 | 95.0% | 95.0% | ◑ |
| | | | | | | 2022/23, Q2 | 94.5% | 92.9% | 2021/22, Q2 | 94.2% | | 2022/23, Q2 | 93.8% | | |
| | | | | | | 2022/23, Q3 | 94.6% | 93.0% | 2021/22, Q3 | 94.6% | | 2022/23, Q3 | 96.0% | | |
| | | | | | | 2021/22, Q4 | 94.5% | 93.0% | 2020/21, Q4 | 95.6% | | 2021/22, Q4 | 95.0% | | |
| | | Population vaccination coverage - Hib / MenC booster | >1 year | High | 95% | 2022/23, Q1 | 92.0% | 89.6% | 2021/22, Q1 | 92.2% | 91.8% | 2022/23, Q1 | 91.6% | 91.9% | ⬆ |
| | | | | | | 2022/23, Q2 | 92.0% | 89.5% | 2021/22, Q2 | 90.9% | | 2022/23, Q2 | 91.1% | | |
| | | | | | | 2022/23, Q3 | 91.1% | 88.9% | 2021/22, Q3 | 91.7% | | 2022/23, Q3 | 92.3% | | |
| | | | | | | 2021/22, Q4 | 92.0% | 89.7% | 2020/21, Q4 | 92.3% | | 2021/22, Q4 | 92.6% | | |
| | | Population vaccination coverage - MMR for one dose | >1 year | High | 95% | 2022/23, Q1 | 92.0% | 89.7% | 2021/22, Q1 | 92.0% | 91.7% | 2022/23, Q1 | 91.4% | 92.1% | ⬆ |
| | | | | | | 2022/23, Q2 | 92.0% | 89.7% | 2021/22, Q2 | 90.8% | | 2022/23, Q2 | 91.1% | | |
| | | | | | | 2022/23, Q3 | 91.1% | 89.0% | 2021/22, Q3 | 91.7% | | 2022/23, Q3 | 93.1% | | |
| | | | | | | 2021/22, Q4 | 92.1% | 89.7% | 2020/21, Q4 | 92.4% | | 2021/22, Q4 | 92.6% | | |
| | 5 Years old | Population vaccination coverage - Dtap / IPV booster | >1 year | High | 95% | 2022/23, Q1 | 85.2% | 83.0% | 2021/22, Q1 | 89.7% | 89.9% | 2022/23, Q1 | 87.0% | 87.1% | ◑ |
| | | | | | | 2022/23, Q2 | 84.4% | 83.4% | 2021/22, Q2 | 87.6% | | 2022/23, Q2 | 85.4% | | |
| | | | | | | 2022/23, Q3 | 85.0% | 84.0% | 2021/22, Q3 | 86.9% | | 2022/23, Q3 | 88.0% | | |
| | | | | | | 2021/22, Q4 | 86.4% | 84.6% | 2020/21, Q4 | 95.5% | | 2021/22, Q4 | 87.9% | | |
| | | Population vaccination coverage - MMR for one dose | >1 year | High | 95% | 2022/23, Q1 | 94.8% | 92.9% | 2021/22, Q1 | 95.4% | 94.7% | 2022/23, Q1 | 94.0% | 94.6% | ◑ |
| | | | | | | 2022/23, Q2 | 94.4% | 92.9% | 2021/22, Q2 | 94.4% | | 2022/23, Q2 | 93.4% | | |
| | | | | | | 2022/23, Q3 | 94.7% | 92.9% | 2021/22, Q3 | 94.1% | | 2022/23, Q3 | 96.3% | | |
| | | | | | | 2021/22, Q4 | 94.8% | 93.5% | 2020/21, Q4 | 95.0% | | 2021/22, Q4 | 94.8% | | |
| | | Population vaccination coverage - MMR for two doses | >1 year | High | 95% | 2022/23, Q1 | 86.5% | 84.4% | 2021/22, Q1 | 90.3% | 89.0% | 2022/23, Q1 | 87.4% | 87.8% | ◑ |
| | | | | | | 2022/23, Q2 | 85.9% | 84.7% | 2021/22, Q2 | 88.4% | | 2022/23, Q2 | 86.8% | | |
| | | | | | | 2022/23, Q3 | 86.6% | 85.2% | 2021/22, Q3 | 87.7% | | 2022/23, Q3 | 88.8% | | |
| | | | | | | 2021/22, Q4 | 87.4% | 85.9% | 2020/21, Q4 | 89.5% | | 2021/22, Q4 | 88.1% | | |
| | | Population vaccination coverage - Hib / Men C booster | >1 year | High | 95% | 2022/23, Q1 | 91.7% | 91.3% | 2021/22, Q1 | 92.4% | 92.1% | 2022/23, Q1 | 92.2% | 92.4% | ⬆ |
| | | | | | | 2022/23, Q2 | 91.7% | 91.2% | 2021/22, Q2 | 92.2% | | 2022/23, Q2 | 91.0% | | |
| | | | | | | 2022/23, Q3 | 90.9% | 91.0% | 2021/22, Q3 | 91.4% | | 2022/23, Q3 | 93.4% | | |
| | | | | | | 2021/22, Q4 | 92.3% | 92.0% | 2020/21, Q4 | 92.3% | | 2021/22, Q4 | 92.8% | | |
| Adolescent and young adults | | Population vaccination coverage - HPV vaccination coverage for one dose (females 12-13 years old) | >1 year | High | 90% | 2021-22 | 67.8% | 69.6% | 2020-21 | 74.7% | | 2021-22 | 81.8% | | ⬆ |
| | | Population vaccination coverage - MenACWY vaccination coverage (14-15 years old) | 2 - 3 years | High | 90% | 2020-21 | 83.5% | 80.9% | 2019-20 | 95.0% | | 2020-21 | 91.9% | | ◑ |
| Adult(+) | | Population vaccination coverage - PPV (%) (aged 65 and over) | 1 - 2 years | High | 65%-75% | 2020-21 | 70.4% | 70.6% | 2019-20 | 65.6% | | 2020-21 | 67.4% | | ⬆ |
| | | Population vaccination coverage - Pertussis (%) (pregnant women) | >1 year | High | N/A | 2022/23, Q1 | 59.1%* | 60.5% | 2021/22, Q1 | 57.7% | 54.1% | 2022/23, Q1 | 50.4% | 53.3% | ◑ |
| | | | | | | 2022/23, Q2 | 59.4%* | 60.3% | 2021/22, Q2 | 53.7% | | 2022/23, Q2 | 52.7% | | |
| | | | | | | 2022/23, Q3 | 60.3%* | 61.4% | 2021/22, Q3 | 52.6% | | 2022/23, Q3 | 56.6% | | |
| | | | | | | 2021/22, Q4 | 62.6%* | 64.0% | 2020/21, Q4 | 52.3% | | 2021/22, Q4 | 53.4% | | |
| | | Population vaccination coverage - Shingles vaccination coverage (70 years old) | >1 year | High | 50%-60% | 2021-22 | 31.7% | 31.2% | 2020-21 | 15.5% | | 2021-22 | 26.7% | | ⬆ |
| | | Population vaccination coverage - Flu 2 years old | >1 year | High | 95%* | Sep 2022 - Jan 2023 | 38.3% | 41.7% | Sep 2021 - Jan 2022 | 47.9% | | Sep 2022 - Jan 2023 | 38.1% | | ◑ |
| | | Population vaccination coverage - Flu 3 years old | >1 year | High | 95%* | Sep 2022 - Jan 2023 | 42.7% | 44.5% | Sep 2021 - Jan 2022 | 49.1% | | Sep 2022 - Jan 2023 | 40.9% | | ◑ |
| | | Population vaccination coverage - Flu reception year (4-5 years old) | >1 year | High | 95%* | Sep 2021 - Jan 2022 | 54.6%* | 56.7% | Sep 2020 - Jan 2021 | 58.8% | | Sep 2021 - Jan 2022 | 51.2% | | ◑ |
| | | Population vaccination coverage - Flu school year 1 (5-6 years old) | >1 year | High | 95%* | Sep 2021 - Jan 2022 | 57.4%* | 58.7% | Sep 2020 - Jan 2021 | 58.0% | | Sep 2021 - Jan 2022 | 55.5% | | ◑ |
| | | Population vaccination coverage - Flu school Year 2 (6-7 years old) | >1 year | High | 95%* | Sep 2021 - Nov 2021 | 56.8%* | 58.6% | Sep 2020 - Jan 2021 | 55.6% | | Sep 2021 - Jan 2022 | 53.3% | | ◑ |

# Health Protection Scorecard, County Indicators

| Data Quality Key | |
|---|---|
| >1 year | Very recent data, likely to be reliable and useful |
| 1 - 2 years | Recent data, likely to be reliable and useful |
| 2 - 3 years | Old data, possibly reliable but should not be used without a data caveat |
| 3+ years | Old data, unlikely to be reliable and should not be used |

Compare to target

Compare to last data collection period

| Meeting national target | | Below national target | | No national target | |
|---|---|---|---|---|---|
| Increased | ◑ | Reduced | ◐ | No change | ➲ |
| Good | ⬆ ⬇ | Bad | ⬆ ⬇ | | |

| Area | Indicator | Time since last update | Good is | National Target | Comparator | | | Northamptonshire ICS | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Previous Data | | | Current Data | | | |
| | | | | | Date | East Midlands | England | Period | Outturn | Average (crude)/Outturn | Period | Outturn | Average (crude)/Outturn | RAG |
| **Seasonal Flu** | Population vaccination coverage - Flu school year 3 (7-8 years old) | >1 year | High | 95%* | Sep 2021 - Nov 2021 | 56%* | 57.8% | Sep 2020 - Jan 2021 | 57.3% | | Sep 2021 - Jan 2022 | 52.9% | | ⬇ |
| | Population vaccination coverage - Flu school year 4 (8-9 years old) | >1 year | High | 95%* | Sep 2021 - Nov 2021 | 55.9%* | 57.2% | Sep 2020 - Jan 2021 | 58.0% | | Sep 2021 - Jan 2022 | 53.3% | | ⬇ |
| | Population vaccination coverage - Flu, under 65 and at risk individuals (%) | >1 year | High | 75% | Sep 2022 - Jan 2023 | 48.7% | 48.6% | Sep 2021 - Jan 2022 | 54.1% | | Sep 2022 - Jan 2023 | 50.5% | | ⬇ |
| | Population vaccination coverage - Flu, aged 65+ (%) | >1 year | High | 75% | Sep 2022 - Jan 2023 | 79.7% | 79.4% | Sep 2021 - Jan 2022 | 83.1% | | Sep 2022 - Jan 2023 | 80.4% | | ⬇ |
| | Population vaccination coverage - Flu, pregnant women (%) | >1 year | High | 75% | Sep 2022 - Jan 2023 | 33.9% | 34.7% | Sep 2021 - Jan 2022 | 34.7% | | Sep 2022 - Jan 2023 | 35.6% | | ⬆ |
| **Environmental Health** | | | | | | | | | | | | | | |
| **Environmental Health** | Fraction of mortality attributable to particular air pollution | 3+ years | Low | N/A | 2019 | 5.3 | 5.1 | 2018 | 5.3 | | 2019 | 5.4 | | ⬆ |
| | Fuel poverty | 2 - 3 years | Low | N/A | 2020 | 14.2% | 13.2% | 2019 | 12.4% | | 2020 | 12.4% | | ➲ |
| | The rate of complaints about noise, per 1,000 | 2 - 3 years | Low | N/A | 2019/20 | 4.2 | 6.4 | 2018/19 | 5.6 | | 2019/20 | 5.4 | | ⬇ |

* Flu monthly figures are accumulative starting from flu vaccination season (September in each year). Children's National target has changed from 75% to 95%. Regional average = Midlands average

# Health Protection Scorecard, County Indicators

| Area | | Indicator | Time since last update | Good is | National Target | Comparator | | | Northamptonshire ICS | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | Previous Data | | | Current Data * | | | |
| | | | | | | Date | East Midlands * | England | Period | Outturn | Average (crude)/Outturn | Period | Outturn | Average (crude)/Outturn | RAG |
| **Infectious Diseases** | | | | | | | | | | | | | | | |
| Tuberculosis | | Tuberculosis incidence (three year average), per 100,000 | >1 year | Low | N/A | 2019-21 | 7 | 7.8 | 2018-20 | 6.4 | | 2019-21 | 5.7 | | ⬇ |
| | | Proportion of pulmonary Tuberculosis cases starting treatment within four months of symptom onset | 3+ years | High | N/A | 2019 | 73.0% | 69.1% | 2018 | 79.3% | | 2019 | 73.1% | | ⬇ (red) |
| | | Proportion of Tuberculosis cases offered an HIV test | 2 - 3 years | High | N/A | 2020 | N/A | 97.4% | 2019 | 89.1% | | 2020 | 89.3% | | ⬆ (green) |
| Blood Borne Viruses | Hepatitis B | Acute hepatitis B incidence rate, per 100,000 | 3+ years | Low | N/A | 2018 | 0.5 | 0.69 | 2017 | 0.13 | | 2018 | 0.00 | | ⬇ |
| | | Under 75 mortality rate from hepatitis B related end-stage liver disease/hepatocellular carcinoma, per 100,000 | 3+ years | Low | N/A | 2017-19 | 0.08 | 0.13 | 2016-18 | 0.05 | | 2017-19 | NA | | ⬆ (red) |
| | | Persons entering drug misuse treatment - number offered and accepted a hepatitis B vaccination as a proportion of all eligible clients in treatment | >1 year | High | N/A | 2022/23, Q1 / 2022/23, Q2 / 2021/22, Q3 / 2021/22, Q4 | N/A / N/A / N/A / N/A | 29.4% / 29.1% / 28.4% / 30.1% | 2021/22, Q1 / 2021/22, Q2 / 2021/22, Q3 / 2020/21, Q4 | 59.1% / 57.4% / 55.0% / 58.5% | 57.5% | 2022/23, Q1 / 2022/23, Q2 / 2022/23, Q3 / 2021/22, Q4 | 35.0% / 28.7% / 18.5% / 49.7% | 33.0% | ⬇ |
| | | Hospital admission rate for hepatitis B related end-stage liver disease/hepatocellular carcinoma, per 100,000 | 3+ years | Low | N/A | 2012/13 - 14/15 | 0.46 | 1.14 | 2011/12 - 2013/14 | 0.71 | | 2012/13 - 14/15 | 0.75 | | ⬆ (red) |
| | Hepatitis C | Hepatitis C detection rate, per 100,000 | 3+ years | Low | N/A | 2017 | N/A | 18.4 | 2016 | 4.6 | | 2017 | 6.0 | | ⬆ (red) |
| | | Under 75 mortality rate from hepatitis C related end-stage liver disease/hepatocellular carcinoma, per 100,000 | 3+ years | Low | N/A | 2017-19 | 0.33 | 0.53 | 2016-18 | 0.88 | | 2017-19 | 0.68 | | ⬇ (green) |
| | | Hospital admission rate for hepatitis C related end-stage liver disease/hepatocellular carcinoma, per 100,000 | 3+ years | Low | N/A | 2012/13 - 2014/15 | 1.7 | 2.4 | 2011/12- 2013/14 | 2.8 | | 2012/13 - 2014/15 | 2.8 | | ➡ |
| | | Persons in drug misuse treatment who inject drugs - Percentage of eligible persons who have received a hepatitis C test | >1 year | High | N/A | 2022/23, Q1 / 2022/23, Q2 / 2021/22, Q3 / 2021/22, Q4 | N/A / N/A / N/A / N/A | 50.3% / 52.3% / 54.4% / 48.0% | 2021/22, Q1 / 2021/22, Q2 / 2021/22, Q3 / 2020/21, Q4 | 66.5% / 67.3% / 68.0% / 66.4% | 67.1% | 2022/23, Q1 / 2022/23, Q2 / 2021/22, Q3 / 2021/22, Q4 | 69.9% / 74.4% / 73.4% / 69.2% | 71.7% | ⬆ (green) |
| | HIV | New HIV diagnosis rate, per 100,000 aged 15+ | 1 - 2 years | Low | N/A | 2021 | 2.8 | 4.8 | 2020 | 4.6 | | 2021 | 4.2 | | ⬇ |
| | | HIV diagnosed prevalence rate, per 1,000 aged 15-59 | 1 - 2 years | Low | <2, 2 to 5, ≥5 | 2020 | 1.58 | 2.34 | 2020 | 2.18 | | 2021 | 2.23 | | ⬆ (red) |
| | | HIV late diagnosis (all CD4 less than 350) (%) | 1 - 2 years | Low | <25%, 25% to 50%, ≥50% | 2019-21 | 52.7% | 43.4% | 2018-20 | 63.7% | | 2019-21 | 62.9% | | ⬇ (red) |
| | | HIV testing coverage, total (%) | 1 - 2 years | High | N/A | 2021 | 36.3% | 45.8% | 2020 | 37.8% | | 2021 | 43.2% | | ⬆ (green) |
| STI | | All new STI diagnoses rate, per 100,000 | 1 - 2 years | Low | N/A | 2021 | 262 | 394 | 2020 | 349 | | 2021 | 198 | | ⬇ |
| | | Syphilis diagnostic rate, per 100,000 | 1 - 2 years | Low | N/A | 2021 | 5.8 | 13.3 | 2020 | 3.70 | | 2021 | 4.80 | | ⬆ (red) |
| | | Gonorrhoea diagnostic rate, per 100,000 | 1 - 2 years | Low | N/A | 2021 | 50 | 90 | 2020 | 35 | | 2021 | 32 | | ⬇ (green) |
| | | Chlamydia detection rate, per 100,000 aged 15-24 | 1 - 2 years | High | <1,900, 1,900 to 2,300, ≥2,300 | 2021 | 1,370 | 1,334 | 2020 | 1,374 | | 2021 | 1,308 | | ⬇ |
| COVID-19 | 18 - 64 Years | Population vaccination coverage - Dose 2 (%) | >1 year | High | N/A | 2022 | 78.7% | 75.3% | 2021 | 74.0% | | 2022 | 76.2% | | ⬆ (green) |
| | | Population vaccination coverage - Booster (%) | >1 year | High | N/A | 2022 | 62.5% | 58.9% | 2021 | 50.7% | | 2022 | 59.9% | | ⬆ (green) |
| | 65+ years | Population vaccination coverage - Dose 2 (%) | >1 year | High | N/A | 2022 | 96.1% | 94.0% | 2021 | 95.4% | | 2022 | 95.6% | | ⬆ (green) |
| | | Population vaccination coverage - Booster (%) | >1 year | High | N/A | 2022 | 93.8% | 91.1% | 2021 | 91.4% | | 2022 | 93.3% | | ⬆ (green) |
| | | Acute Infectious Hepatitis notifications | >1 year | Low | N/A | 2021 | 8 | 202 | 2020 | 3 | | 2021 | 1 | | ⬇ (green) |

# Health Protection Scorecard, County Indicators

| Data Quality Key | |
|---|---|
| >1 year | Very recent data, likely to be reliable and useful |
| 1 - 2 years | Recent data, likely to be reliable and useful |
| 2 - 3 years | Old data, possibly reliable but should not be used without a data caveat |
| 3+ years | Old data, unlikely to be reliable and should not be used |

Compare to target

Compare to last data collection period

| | Meeting national target | | Below national target | | No national target |
|---|---|---|---|---|---|
| | Increased | ⬆ | Reduced | ⬇ | No change ➡ |
| | Good | 🟢⬆ 🟢⬇ | Bad | 🔴⬆ 🔴⬇ | |

| Area | Indicator | Time since last update | Good is | National Target | Comparator | | | Northamptonshire ICS | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Previous Data | | | Current Data * | | |
| | | | | | Date | East Midlands * | England | Period | Outturn | Average (crude)/Outturn | Period | Outturn | Average (crude)/Outturn | RAG |
| Other infectious diseases | Acute Meningitis notifications | >1 year | Low | N/A | 2021 | 4 | 58 | 2020 | 2 | | 2021 | 1 | | 🟢⬇ |
| | Diphtheria notifications | >1 year | Low | N/A | 2021 | 0.0 | 4.0 | 2020 | 0.0 | | 2021 | 0 | | ➡ |
| | Enteric fever (Typhoid or paratyphoid fever) notifications | >1 year | Low | N/A | 2021 | 0.0 | 21.0 | 2020 | 1.0 | | 2021 | 0 | | 🟢⬇ |
| | Food poisoning notifications | >1 year | Low | N/A | 2021 | 42 | 4,391 | 2020 | 6.0 | | 2021 | 1 | | 🟢⬇ |
| | Infectious bloody diarrhoea notifications | >1 year | Low | N/A | 2021 | 16 | 176 | 2020 | 3.0 | | 2021 | 2 | | 🟢⬇ |
| | Invasive group A streptococcal disease notifications | >1 year | Low | N/A | 2021 | 5 | 79 | 2020 | 2.0 | | 2021 | 0 | | 🟢⬇ |
| | Legionnaires' Disease notifications | >1 year | Low | N/A | 2021 | 6.0 | 90.0 | 2020 | 2.00 | | 2021 | 0 | | 🟢⬇ |
| | Measles incidence rate, per 100,000 | >1 year | Low | N/A | 2021 | 0 | 0.0 | 2020 | 0.0 | | 2021 | 0 | | ➡ |
| | Mumps notifications | >1 year | Low | N/A | 2021 | 276.0 | 3,214 | 2020 | 78.0 | | 2021 | 29 | | 🟢⬇ |
| | Rubella notifications | >1 year | Low | N/A | 2021 | 6 | 67 | 2020 | 2.0 | | 2021 | 1 | | 🟢⬇ |
| | Scarlet Fever notifications | >1 year | Low | N/A | 2021 | 359 | 2,659 | 2020 | 127.0 | | 2021 | 42 | | 🟢⬇ |
| | Tuberculosis notifications | >1 year | Low | N/A | 2021 | 366 | 4,787 | 2020 | 39.0 | | 2021 | 52 | | 🔴⬆ |
| | Whooping Cough notifications | >1 year | Low | N/A | 2021 | 57 | 527 | 2020 | 29.0 | | 2021 | 4 | | 🟢⬇ |

* Flu monthly figures are accumulative starting from flu vaccination season (September in each year). Children's National target has changed from 75% to 95%. Regional average = Midlands average

# Health Protection Scorecard, Screening & Hospital Indicators

## Cancer & Non-Cancer Screening

| Area | Indicator | Time since last update | Good is | Target | Comparator Date | Comparator England | Previous Data Period | Previous Data Outturn | Average (crude) | Current Data Period | Current Data Outturn | Average (crude) | RAG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer Screening | Cervical screening coverage, aged 25 to 49 years | >1 year | High | 80% | 2022/23, Q1 | 68.3% | 2021/22, Q1 | 69.6% | 69.0% | 2022/23, Q1 | 68.5% | 68.3% | ⬇ |
| | | | | | 2022/23, Q2 | 67.1% | 2021/22, Q2 | 68.8% | | 2022/23, Q2 | 67.4% | | |
| | | | | | 2021/22, Q3 | 68.1% | 2020/21, Q3 | 68.2% | | 2021/22, Q3 | 68.3% | | |
| | | | | | 2021/22, Q4 | 68.6% | 2020/21, Q4 | 69.2% | | 2021/22, Q4 | 69.0% | | |
| | Cervical screening coverage, aged 50 to 64 years | >1 year | High | 80% | 2022/23, Q1 | 75.0% | 2021/22, Q1 | 74.1% | 74.1% | 2022/23, Q1 | 73.5% | 73.6% | ⬇ |
| | | | | | 2022/23, Q2 | 74.8% | 2021/22, Q2 | 73.8% | | 2022/23, Q2 | 73.4% | | |
| | | | | | 2021/22, Q3 | 74.8% | 2020/21, Q3 | 74.1% | | 2021/22, Q3 | 73.6% | | |
| | | | | | 2021/22, Q4 | 75.0% | 2020/21, Q4 | 74.3% | | 2021/22, Q4 | 73.7% | | |
| | Bowel screening coverage | >1 year | High | Acceptable ≥ 52.0%, Achievable ≥ 60.0% | 2022/23, Q1 | 67.7% | 2021/22, Q1 | 69.7% | 70.5% | 2022/23, Q1 | 68.1% | 68.2% | ⬇ |
| | | | | | 2022/23, Q2 | 66.1% | 2021/22, Q2 | 70.4% | | 2022/23, Q2 | 68.1% | | |
| | | | | | 2021/22, Q3 | 66.8% | 2020/21, Q3 | 69.3% | | 2021/22, Q3 | 67.9% | | |
| | | | | | 2021/22, Q4 | 67.0% | 2020/21, Q4 | 72.6% | | 2021/22, Q4 | 68.6% | | |
| | Breast screening coverage | >1 year | High | Acceptable ≥ 70.0%, Achievable ≥ 80.0% | 2022/23, Q1 | 55.5% | 2021/22, Q1 | 63.2% | 60.5% | 2022/23, Q1 | 66.9% | 59.3% | ⬇ |
| | | | | | 2022/23, Q2 | 56.7% | 2021/22, Q2 | 57.7% | | 2022/23, Q2 | 62.2% | | |
| | | | | | 2021/22, Q3 | 54.5% | 2020/21, Q3 | n/a | | 2021/22, Q3 | 52.7% | | |
| | | | | | 2021/22, Q4 | 53.3% | 2020/21, Q4 | n/a | | 2021/22, Q4 | 55.5% | | |
| Non-Cancer Screening | Abdominal Aortic Aneurysm screening coverage (cumulative annual %) | >1 year | High | Acceptable ≥ 85.0%, Achievable ≥ 95.0% | 2022/23, Q1 | 13.2% | 2021/22, Q1 | 7.0% | N/A | 2022/23, Q1 | 17.0% | N/A | |
| | | | | | 2022/23, Q2 | 31.8% | 2021/22, Q2 | 16.2% | | 2022/23, Q2 | 41.3% | | |
| | | | | | 2021/22, Q3 | 35.9% | 2020/21, Q3 | 34.7% | | 2021/22, Q3 | 41.5% | | |
| | | | | | 2021/22, Q4 | 59.5% | 2020/21, Q4 | 49.9% | | 2021/22, Q4 | 73.7% | | |
| | Diabetic eye screening - uptake | >1 year | High | Acceptable ≥ 75.0%, Achievable ≥ 85.0% | 2022/23, Q1 | 78.6% | 2021/22, Q1 | 63.3% | 57.5% | 2022/23, Q1 | 71.9% | 72.4% | ⬆ |
| | | | | | 2022/23, Q2 | 78.3% | 2021/22, Q2 | 69.1% | | 2022/23, Q2 | 71.3% | | |
| | | | | | 2021/22, Q3 | 77.6% | 2020/21, Q3 | 51.3% | | 2021/22, Q3 | 73.9% | | |
| | | | | | 2021/22, Q4 | 78.4% | 2020/21, Q4 | 46.4% | | 2021/22, Q4 | 72.5% | | |
| Newborn Screening (ICS) | Newborn blood spot coverage (ICS) | >1 year | High | Acceptable ≥ 95.0%, Achievable ≥ 99.0% | 2022/23, Q1 | 97.3% | 2021/22 Q1 | 96.6% | 96.9% | 2022/23 Q1 | 97.8% | 97.4% | ⬆ |
| | | | | | 2022/23, Q2 | 97.2% | 2021/22, Q2 | 97.5% | | 2022/23, Q2 | 97.5% | | |
| | | | | | 2021/22, Q3 | 97.1% | 2020/21, Q3 | 96.3% | | 2021/22, Q3 | 95.9% | | |
| | | | | | 2021/22, Q4 | 97.0% | 2020/21, Q4 | 97.3% | | 2021/22, Q4 | 98.3% | | |

## Antenatal & Newborn Screening

| Area | Indicator | Time since last update | Good is | Target | Comparator Date | Comparator England | NGH Previous Period | NGH Previous Outturn | NGH Prev Avg (crude) | NGH Current Period | NGH Current Outturn | NGH Curr Avg (crude) | NGH RAG | KGH Previous Period | KGH Previous Outturn | KGH Prev Avg (crude) | KGH Current Period | KGH Current Outturn | KGH Curr Avg (crude) | KGH RAG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antenatal Screening | HIV Coverage | >1 year | High | Acceptable ≥ 95.0%, Achievable ≥ 99.0% | 2022/23, Q1 | 99.8% | 2021/22, Q1 | 99.7% | 99.7% | 2022/23, Q1 | 99.7% | 99.8% | ⬆ | 2021/22, Q1 | 99.3% | 99.7% | 2022/23, Q1 | 100.0% | 99.8% | ⬆ |
| | | | | | 2022/23, Q2 | 99.8% | 2021/22, Q2 | 99.7% | | 2022/23, Q2 | 99.5% | | | 2021/22, Q2 | 99.6% | | 2022/23, Q2 | 99.7% | | |
| | | | | | 2021/22, Q3 | 99.8% | 2020/21, Q3 | 99.9% | | 2021/22, Q3 | 100.0% | | | 2020/21, Q3 | 99.8% | | 2021/22, Q3 | 99.7% | | |
| | | | | | 2021/22, Q4 | 99.8% | 2020/21, Q4 | 99.6% | | 2021/22, Q4 | 99.8% | | | 2020/21, Q4 | 100.0% | | 2021/22, Q4 | 99.6% | | |
| | Hep B Coverage | >1 year | High | Acceptable ≥ 95.0%, Achievable ≥ 99.0% | 2022/23, Q1 | 99.8% | 2021/22, Q1 | 99.7% | 99.8% | 2022/23, Q1 | 99.7% | 99.7% | ⬇ | 2021/22, Q1 | 99.5% | 99.7% | 2022/23, Q1 | 100.0% | 99.8% | ⬆ |
| | | | | | 2022/23, Q2 | 99.8% | 2021/22, Q2 | 99.7% | | 2022/23, Q2 | 99.4% | | | 2021/22, Q2 | 99.6% | | 2022/23, Q2 | 99.7% | | |
| | | | | | 2021/22, Q3 | 99.8% | 2020/21, Q3 | 100.0% | | 2021/22, Q3 | 100.0% | | | 2020/21, Q3 | 99.8% | | 2021/22, Q3 | 99.7% | | |
| | | | | | 2021/22, Q4 | 99.8% | 2020/21, Q4 | 99.6% | | 2021/22, Q4 | 99.8% | | | 2020/21, Q4 | 100.0% | | 2021/22, Q4 | 99.6% | | |
| | Syphilis Coverage | >1 year | High | Acceptable ≥ 95.0%, Achievable ≥ 99.0% | 2022/23, Q1 | 99.8% | 2021/22, Q1 | 99.7% | 99.8% | 2022/23, Q1 | 99.7% | 99.8% | → | 2021/22, Q1 | 99.5% | 99.7% | 2022/23, Q1 | 100.0% | 99.8% | ⬆ |
| | | | | | 2022/23, Q2 | 99.8% | 2021/22, Q2 | 99.7% | | 2022/23, Q2 | 99.5% | | | 2021/22, Q2 | 99.6% | | 2022/23, Q2 | 99.7% | | |
| | | | | | 2021/22, Q3 | 99.8% | 2020/21, Q3 | 100.0% | | 2021/22, Q3 | 100.0% | | | 2020/21, Q3 | 99.8% | | 2021/22, Q3 | 99.7% | | |
| | | | | | 2021/22, Q4 | 99.8% | 2020/21, Q4 | 99.6% | | 2021/22, Q4 | 99.8% | | | 2020/21, Q4 | 100.0% | | 2021/22, Q4 | 99.6% | | |
| | Sickle Cell and Thalassemia Coverage | >1 year | High | Acceptable ≥ 95.0%, Achievable ≥ 99.0% | 2022/23, Q1 | 99.7% | 2021/22, Q1 | 99.4% | 99.6% | 2022/23, Q1 | 99.7% | 99.7% | ⬆ | 2021/22, Q1 | 99.5% | 99.8% | 2022/23, Q1 | 100.0% | 99.7% | ⬇ |
| | | | | | 2022/23, Q2 | 99.7% | 2021/22, Q2 | 99.5% | | 2022/23, Q2 | 99.5% | | | 2021/22, Q2 | 99.6% | | 2022/23, Q2 | 99.5% | | |
| | | | | | 2021/22, Q3 | 99.7% | 2020/21, Q3 | 99.7% | | 2021/22, Q3 | 99.7% | | | 2020/21, Q3 | 99.9% | | 2021/22, Q3 | 99.7% | | |
| | | | | | 2021/22, Q4 | 99.7% | 2020/21, Q4 | 99.4% | | 2021/22, Q4 | 99.8% | | | 2020/21, Q4 | 100.0% | | 2021/22, Q4 | 99.6% | | |
| Newborn Screening | Hearing Coverage | >1 year | High | Acceptable ≥ 95.0%, Achievable ≥ 99.0% | 2022/23, Q1 | 98.6% | 2021/22, Q1 | 99.7% | 99.1% | 2022/23, Q1 | 97.7% | 98.4% | ⬇ | 2021/22, Q1 | 99.0% | 99.1% | 2022/23, Q1 | 99.8% | 99.1% | ⬆ |
| | | | | | 2022/23, Q2 | 98.5% | 2021/22, Q2 | 99.1% | | 2022/23, Q2 | 97.6% | | | 2021/22, Q2 | 99.2% | | 2022/23, Q2 | 98.6% | | |
| | | | | | 2021/22, Q3 | 98.0% | 2020/21, Q3 | 98.7% | | 2021/22, Q3 | 99.1% | | | 2020/21, Q3 | 98.8% | | 2021/22, Q3 | 99.1% | | |
| | | | | | 2021/22, Q4 | 98.1% | 2020/21, Q4 | 98.7% | | 2021/22, Q4 | 99.0% | | | 2020/21, Q4 | 99.4% | | 2021/22, Q4 | 99.0% | | |
| | Physical Examination Coverage | >1 year | High | Acceptable ≥ 95.0%, Achievable ≥ 99.0% | 2022/23, Q1 | 96.3% | 2021/22, Q1 | 97.2% | 98.0% | 2022/23, Q1 | 96.6% | 96.7% | ⬇ | 2021/22, Q1 | 96.8% | 96.9% | 2022/23, Q1 | 96.0% | 95.6% | ⬇ |
| | | | | | 2022/23, Q2 | 96.3% | 2021/22, Q2 | 97.8% | | 2022/23, Q2 | 95.5% | | | 2021/22, Q2 | 96.9% | | 2022/23, Q2 | 93.8% | | |
| | | | | | 2021/22, Q3 | 96.4% | 2020/21, Q3 | 98.6% | | 2021/22, Q3 | 96.9% | | | 2020/21, Q3 | 97.0% | | 2021/22, Q3 | 95.8% | | |
| | | | | | 2021/22, Q4 | 96.5% | 2020/21, Q4 | 98.5% | | 2021/22, Q4 | 97.6% | | | 2020/21, Q4 | 96.8% | | 2021/22, Q4 | 96.9% | | |